Syndax plummets as IPF asset axatilimab fails in phase 2 trial (SNDX:NASDAQ)
· seekingalpha.com
Syndax (SNDX) plunges after hours as axatilimab fails Phase 2 idiopathic pulmonary fibrosis endpoint.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...